{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092253","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.261303+00:00","generated_at":"2026-05-31T11:37:00.332529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed","bullets":["Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.","Net earnings $242.8M GAAP; adjusted net earnings $415.0M.","FY 2024 reported revenue guidance lowered to 4.0%-5.0% on FX; CC revenue growth 5.0%-6.0% and adjusted EPS $8.00-$8.15 reaffirmed.","Signed definitive agreement to acquire OrthoGrid Systems (AI hip guidance); also entered THINK Surgical and CBRE partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092253","json":"https://secwatch.observer/filing/0000950170-24-092253.json","markdown":"https://secwatch.observer/filing/0000950170-24-092253.md","text":"https://secwatch.observer/filing/0000950170-24-092253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/0000950170-24-092253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/zbh-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:37:00.332529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}